Evidence map›Paper›PMID 37766191›Full record

ArticleViruses2023

Innate Immune Gene Polymorphisms and COVID-19 Prognosis.

Evangelos Bakaros, Ioanna Voulgaridi, Vassiliki Paliatsa, Nikolaos Gatselis, Georgios Germanidis, Evangelia Asvestopoulou, Stamatia Alexiou, Elli Botsfari, Vasiliki Lygoura, Olga Tsachouridou and 10 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Role ofCentral-European journal of immunology · 2025
    Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Evangelos BakarosDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0003-1670-6895
Ioanna VoulgaridiLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.ORCID 0000-0002-7352-0934
Vassiliki PaliatsaDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Nikolaos GatselisDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, Full Member of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, 41110 Larissa, Greece.ORCID 0000-0002-3715-8640
Georgios GermanidisFirst Internal Medicine Department, Infectious Diseases Division, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.ORCID 0000-0001-7985-3118
Evangelia AsvestopoulouDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Stamatia AlexiouDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Elli BotsfariDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Vasiliki LygouraDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, Full Member of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, 41110 Larissa, Greece.
Olga TsachouridouFirst Internal Medicine Department, Infectious Diseases Division, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Iordanis MimtsoudisFirst Internal Medicine Department, Infectious Diseases Division, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Maria TseroniNational Public Health Organization, 15123 Athens, Greece.
Styliani SarrouDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0001-8134-9228
Varvara A MouchtouriLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.
Katerina DadouliLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.ORCID 0000-0002-8821-0795
Fani KalalaDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Simeon MetallidisFirst Internal Medicine Department, Infectious Diseases Division, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
George DalekosDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, Full Member of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, 41110 Larissa, Greece.
Christos HadjichristodoulouLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.ORCID 0000-0002-4769-8376
Matthaios SpeletasDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0003-1287-7734
University of Thessaly · GRAristotle University of Thessaloniki · GRUniversity Hospital of Larissa · GRNational Public Health Organization · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is characterized by a heterogeneous clinical presentation and prognosis. Risk factors contributing to the development of severe disease include old age and the presence of comorbidities. However, the genetic background of the host has also been recognized as an important determinant of disease prognosis. Considering the pivotal role of innate immunity in the control of SARS-CoV-2 infection, we analyzed the possible contribution of several innate immune gene polymorphisms (including

Indexed as

COVID-19AgedCARD Signaling Adaptor ProteinsHumansImmunity, InnateInterleukin-18Neoplasm ProteinsPolymorphism, GeneticPrognosisRisk FactorsSARS-CoV-2Toll-Like Receptor 2Toll-Like Receptor 4CARD8 protein, humanCARD Signaling Adaptor ProteinsInterleukin-18Neoplasm ProteinsToll-Like Receptor 2Toll-Like Receptor 4CARD8CD14CD40COVID-19IL18innate immunitypolymorphismprognosisTLR2TLR4

Identifiers

PMID37766191
PMCPMC10537595
OpenAlexW4386068183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.